Advertisement
UK markets open in 4 hours 56 minutes
  • NIKKEI 225

    37,843.76
    -118.04 (-0.31%)
     
  • HANG SENG

    16,263.50
    +11.66 (+0.07%)
     
  • CRUDE OIL

    82.75
    +0.06 (+0.07%)
     
  • GOLD FUTURES

    2,382.30
    -6.10 (-0.26%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • Bitcoin GBP

    49,520.09
    -1,953.86 (-3.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     
  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     

Why Bluebird Bio Stock Is Sinking This Week

Why Bluebird Bio Stock Is Sinking This Week

Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.